StemGenex in SoCal and stem cell marketing hype

This interesting article from today’s Los Angeles Times is about the La Jolla-based company StemGenex. I do know of some people in the MSA community and PD community who have contacted StemGenex about their stem cell “treatment.”

StemGenex’s director of media and community relations told the article’s author that the company’s “principal purpose is helping people with unmet clinical needs achieve optimum health and better quality of life,” and that it has “anecdotal feedback … from our patients that their symptoms have dramatically improved and their quality of life has substantially increased.”

The author, Michael Hiltzik, points out:

“But on its website, the group disavows any claim that ‘treatment using autologous stem cells [that is, cells drawn from the patient’s own body] are a cure for any condition, disease, or injury. ‘ It acknowledges that ‘stem cell therapy is not FDA approved and is not a cure for any medical condition,’ and that U.S. health insurance companies won’t cover the procedure, which costs $14,900.”

Mr. Holtzik has lots of negative things to say about StemGenex and its website.  He followed up with the company about its claim of accreditation as an outpatient surgical facility.  After his questions, the company removed that accreditation from its website.

The author reports that two researchers — Leigh Turner, University of Minnesota bioethicist, and Paul Knoepfler, UC Davis stem cell scientist — found 570 clinics involved in “stem cell tourism,” with “hot spots” in Southern California, Phoenix, New York, San Antonio, and Austin.  Researchers are very alarmed about what’s going on in clinics around the US.

Check out the full article here:

www.latimes.com/business/hiltzik/la-fi-hiltzik-stem-cell-scam-20160821-snap-story.html

BUSINESS
These new stem cell treatments are expensive — and unproven
LA Times
Michael Hiltzik, columnist
August 19, 2016

Robin

Differences between PD and atypical parkinsonian disorders

This post may be of interest to those people looking for a short overview of the four atypical parkinsonism disorders – PSP, CBD, MSA, and DLB – or who want to know the key differences in typical Parkinson’s Disease and the atypicals as a group.

An overview of diagnosing atypical parkinsonian disorders was published in the August 2016 issue of Continuum, a journal for neurologists.

The article includes a list of symptoms (“red flags”) that are “predictive of atypical parkinsonism”:

Rapid disease progression
Early gait instability, falls
Absence or paucity of tremor
Irregular jerky tremor, myoclonus
Poor/absent response to levodopa

The article also includes a list of symptoms that should lead a neurologist to think about specific atypical parkinsonism disorders such as:

PSP:  abnormal eye movements; early, prominent dementia

CBS:  apraxia; alien limb; myoclonus; early, prominent dementia

MSA:  pyramidal tract/cerebellar signs; dysautonomia; severe dysarthria; dysphonia; stridor

DLB:  early, prominent dementia

I’m very surprised hallucinations, delusions, and fluctuating cognition were not listed as red flags for DLB!

The abstract is available at no charge. Amazingly, the full article seems to be available at no charge; grab it while you can! See:

Diagnostic Approach to Atypical Parkinsonian Syndromes.
Nikolaus R. McFarland
Continuum. 2016 Aug;22(4 Movement Disorders):1117-42.
PubMed ID#: 27495201

Link to Abstract

Link to Full article

Happy reading!

Robin

 

Baylor’s Overview of Atypical Parkinsonism

Joseph Jankovic, MD, is a movement disorder specialist at Baylor College of Medicine in Houston.  This webpage from 2011 is an overview of atypical parkinsonism.  There’s a quick overview of Parkinson’s Disease (PD) and then Dr. Jankovic explains how the atypical parkinsonism forms differ from PD.  Most of the text is about progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).  There is some info about dementia with Lewy bodies (DLB), cortico-basal ganglionic degeneration (CBD), and vascular parkinsonism.  Copied below is most of the text from the webpage and a link to it.

You might also want to check out Dr. Jankovic’s table of differential diagnosis.  He indicates which symptoms or conditions are present or not present in various atypical parkinsonism forms.  Copied below is a link to the table plus my comments about the table.

Thanks to Sue Buff, in the PD community, for pointing out this webpage to me.

Robin

—————————————————————

www.bcm.edu/healthcare/care-centers/parkinsons/conditions/atypical-parkinsonism

Atypical Parkinsonism
Baylor College of Medicine
by Joseph Jankovic, MD
2011

Parkinson’s disease is a progressive brain disorder which usually produces some combination of the following symptoms:
* Tremor at rest
* Slowed movement
* Stiffness or rigidity of muscles
* Unsteadiness when standing or walking
* Freezing” or sudden loss of ability to move (as if the feet are “glued” to the floor).

Parkinson’s disease (PD) results from dying off (degeneration) of certain nerve cells found in a deep part of the brain (brainstem) called the substantia nigra. The reason for the cell death is unknown. These cells produce a neurotransmitter chemical called dopamine. It is the depletion of dopamine in the brain that results in symptoms of PD. Initially, Parkinson’s symptoms improve with dopamine replacement in the form of levodopa (Sinemet). Although the nerve cells in the substantia nigra, which make dopamine, are dying, the nerve cells in the basal ganglia (striatum), which are normally stimulated by dopamine, have well preserved dopamine receptors and are therefore still responding to dopamine. The cornerstone of medical treatment of PD is administration of levodopa, which is taken up and converted into dopamine by the brain.

“Atypical” Parkinsonism and How It Differs From Parkinson’s Disease

Parkinsonism refers to a set of symptoms typically seen in Parkinson’s disease, but caused by other disorders. Atypical parkinsonism includes a variety of neurological disorders in which patients have some clinical features of PD, but the symptoms are caused not only by cell loss in the substantia nigra (the brain area most affected in classic PD), but also by additional degeneration of cells in the parts of the nervous system that normally contain dopamine receptors (striatum). In other words, the patients look like they have PD, but the cause of their symptoms is different from that of classic PD. Patients with atypical parkinsonism have symptoms similar to PD, including resting tremors, slowed movement, stiffness, gait difficulty and postural instability, but in addition have symptoms and signs that are not typically present in PD, hence the term “Parkinsonism plus syndrome.”

The additional problems may include inability to look up and down (vertical gaze palsy) and early postural instability, such as seen in progressive supranuclear palsy (PSP), the most common form of atypical parkinsonism. Patients with PSP often have the “procerus sign” which is a particular “worried” facial expression.

The second most common form of atypical parkinsonism is multiple system atrophy (MSA), previously also referred to as Shy-Drager syndrome or olivopontocerebellar atrophy. Patients with MSA are typically distinguished from those with PD by the presence of autonomic features such as unstable blood pressure which falls drastically upon standing (orthostatic hypotension), early disturbance of sexual, bladder, and bowel dysfunction, reddish-bluish discoloration of skin (e.g. the “cold hand” sign), and marked sleep disturbance (e.g. acting out of dreams and sleep apnea). Other typical features of MSA include forward head tilt (anterocollis) or a body tilt when sitting (Pisa sign), loss of coordination, and rapidly progressive course with inability to ambulate usually within the first 3-5 years after onset. MSA is divided into MSA-C (cerebellar variant) which has more symptoms of ataxia (incoordination) and MSA-P (parkinsonian variant) which has more parkinsonian symptoms but is unresponsive to the usual therapy for Parkinson’s disease (levodopa).

Another common cause of atypical parkinsonism is “vascular parkinsonism” caused by multiple, usually very minute, strokes. These patients usually have more symptoms in the lower extremities (lower body parkinsonism) with walking difficulties, balance problems and falls.

Other forms of atypical parkinsonism are Dementia with Lewy bodies (DLB) and cortico-basal ganglionic degeneration (CBD). Patients with DLB have, in addition to the parkinsonian features, early dementia (preceding or co-occurring with the parkinsonian symptoms), visual hallucinations (seeing people, animals or objects that are not real), their symptoms fluctuating, with “good days” and “bad days.” Patients with CBD usually present with asymmetric stiffness, apraxia (inability to carry out learned purposeful movements), alien limb (the hand or the leg seem to have “a mind of their own”), and limb dystonia (abnormal sustained muscle contractions causing abnormal postures and twisting). Poor or no response to levodopa is common feature to all forms of atypical parkinsonism.

In contrast to typical PD, in which dopamine receptors are spared, patients with atypical parkinsonian disorders have lost their dopamine receptors and therefore they do not respond to levodopa as well as those with typical PD. This can be demonstrated by special imaging such as positron emission tomography (PET) and dopamine transporter imaging (DAT-SPECT). MRI may be also helpful in differentiating PD from atypical parkinsonism.

Causes

There are probably many causes of atypical parkinsonism, but no one specific cause has been identified. There are many articles (see references) that describe some of the research into the causes of these disorders. Although it is not yet known what causes atypical parkinsonism, only one member of a family is usually affected and, therefore, these disorders are thought to be sporadic and not inherited. This is in contrast to typical PD where genetic factors seem to be quite important. The various atypical parkinsonian syndromes are classified according to the patterns of damage they produce in the nervous system, the constellation of clinical symptoms they cause, and their natural course.

Support Groups for Patients and Their Families

Patients affected with atypical parkinsonism and their families should consider joining national or local PD support groups. Membership in these organizations facilitates exchange of information and members can obtains “tips” that may be useful in coping with the physical and mental disabilities associated with these disorders. Also, many local support groups offer exercise therapy which may be helpful to some patients. With the emotional support of family members and with expert medical management guided by a knowledgeable and compassionate physician, many patients with atypical parkinsonism can lead enjoyable and productive lives.
www.bcm.edu/healthcare/care-centers/parkinsons/conditions/atypical-parkinsonism/parkinsonism-plus-syndromes

Table 1 – Parkinsonism Plus Syndromes: Differential Diagnosis

Robin’s note:  This table identifies which symptoms or conditions are present or not present in atypical parkinsonism disorders.  The symptoms or conditions include bradykinesia, rigidity, gait disturbance, tremor, ataxia, dysautonomia, dementia, dysarthria/dysphagia, dystonia, eyelid apraxia, limb apraxia, motor neuron disease, myoclonus, neuropathy, oculomotor deficit, sleep impairment, asymmetric findings, levodopa response, levodopa dyskinesia, family history, putaminal T2 hypo-intensity, and Lewy bodies.   Disorders include PD, PSP, MSA-P, MSA-C, CBD, DLB, and PDACG (parkinsonism-dementia-ALS complex of Guam).

Robin’s evaluation:  I disagree with some of this chart.  For example, tremor is present in PSP-parkinsonism.  And tremor can be present in DLB.

 

Update on nilotinib, including MJFF webinar on Tuesday, Aug 2

This post may be of most interest to those dealing with Lewy Body Dementia (Dementia with Lewy Bodies and Parkinson’s Disease Dementia).

I first started hearing about the leukemia drug nilotinib back in 2013.  You can find an email sent to the group back in 2013 here:

www.brainsupportnetwork.org/early-research-cancer-drug-nilotinib/

In 2013, Georgetown published some basic research that showed that nilotinib getting rid of alpha-synuclein in the brains of transgenic mice with Parkinson’s.  A Georgetown press release mentioned that they wanted to do phase II studies in PD, LBD, MSA, and PSP — a surprising combination since PSP is not an alpha-synuclein disorder.

In October 2015, Georgetown announced results of a phase I clinical trial of nilotinib in 12 patients for a 6-month period.  Unfortunately there was a mix of diagnoses — 5 had a DLB (dementia with Lewy bodies), 3 had PD-MCI (PD-mild cognitive impairment), 2 had PDD (Parkinson’s disease with dementia), one had PD plus MCI, and one had PD.  Phase I studies are safety studies so I found it confusing that the researchers claimed the “drug improved cognition, motor skills, and non-motor function” in the 11 patients who completed the study.  (One had to drop out due to a serious side effect.)  The study size was very small and there was no placebo-control.  Also, the cancer drug costs several thousand dollars per month.

In November 2015, I asked several movement disorder specialists about use of nilotinib for PD or any of the atypical parkinsonism disorders.  All of the MDs scoffed at the idea.  One said that the nurse in the movement disorders clinic where he works worked for many years in oncology.  That nurse was frightened by the idea that anyone without leukemia would take nilotinib.

In December 2015, I learned that a member of our local support group (whose husband may have LBD) was able to obtain a prescription from a local physician for nilotinib.  It was costing them a bundle.

People are still talking about nilotinib, especially in the PD and LBD communities.  The Georgetown team’s phase I results were finally published in July 2016.  You can read the results here:

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
content.iospress.com/articles/journal-of-parkinsons-disease/jpd160867

Along with the Georgetown results, the journal published an accompanying editorial titled “Nilotinib – Differentiating the Hope from the Hype.”  The authors of the editorial said:  “We debate the safety of Nilotinib and the reported efficacy signals.  We emphasize that due to the small sample size, and lack of a control group, it is impossible to rule out a placebo effect.”  You can read that editorial here:

Nilotinib – Differentiating the Hope from the Hype
content.iospress.com/download/journal-of-parkinsons-disease/jpd160904?id=journal-of-parkinsons-disease%2Fjpd160904

If nilotinib is of interest to you, I’d suggest checking out this Michael J. Fox Foundation overview of the scientific rationale behind nilotinib:

www.michaeljfox.org/foundation/news-detail.php?nilotinib-update-where-we-stand-with-cancer-drug-for-parkinson

Or, if you still want more, the Michael J. Fox Foundation will be having a webinar on Tuesday, August 2nd, from 9 to 10am CA time about nilotinib as a possible treatment for PD.

You can register here:

www.michaeljfox.org/understanding-parkinsons/webinar-registration.php?id=11&e=1224270

The panelists “will discuss the scientific rationale behind nilotinib for Parkinson’s, findings from recent research and next steps in the study of this drug.  Q & A with the audience will follow the discussion.”

Robin

 

“What Are the Other Parkinsonisms?” Webinar, Aug 18, 9am CA time

The Michael J. Fox Foundation has a terrific monthly — Third Thursdays — webinar series. Finally they are getting around to the atypical parkinsonism disorders next month, Thursday, August 18th at 9am California time. (….though it seems that there will still be a Parkinson’s Disease angle on the webinar.)

If you are not able to participate in the one-hour webinar live, I encourage you to register for it so that you’ll receive notice when the recording is available online. Usually the recording is available within a week of the webinar.

Copied below are the details from the MJFF website.

Robin


Michael J. Fox Foundation
Third-Thursday Webinar
Thursday, August 18 @ 12 p.m. ET / 9 a.m. PT

In this webinar we’ll discuss atypical parkinsonisms of corticobasal degeneration, multiple system atrophy, Lewy body dementia and progressive supranuclear palsy. What are the similarities and differences? Could treatments for one condition help those with another, including Parkinson’s disease?

Click here and then on the orange REGISTER NOW button:

www.michaeljfox.org/page.html?hot-topics-webinar-series